Identification and Analysis of Ardisia humilis as Potential Antihyperlipidemic by Network Pharmacology Followed by Molecular Docking

Abstract

Objective: Hyperlipidemia is increasing lipids in a body that are risk factors for cardiovascular disease that increased last over 30 years. Natural products have a large portion as pharmacological agents, particularly in disease therapies. The pharmacological activity of natural product remedies has been thoroughly screened using high approaches in drug discovery. Lampeni, also known as Ardisia humilis Vahl, is utilized for various illnesses such as vertigo, rheumatism, and skin ulcers, and as a stimulant, carminative, andantidiarrheall.Previous studies have shown that feeding Swiss albino rats alcohol extract at 200mg/KgBW could decrease LDL, triglycerides, total cholesterol, and VLDL and increase HDL. Method: This study aimed to predict Lampenileaf's network pharmacology as a potential for hyperlipidemiausing multiple ethnobotanical databases and software. This research was cond.This is in silico. Results: The result of Lampeni leaf is almost all bioactive compounds targeted hyperlipidemia-associated genes.Compounds with the highest potential of Hyperlipidemia are Ardisinol II, Bilobol, ArdisiphenolB, Maesaquinone, Beta amiryn, and Embelin. IL6, HSP90AA1, EGFR, MAPK3, SRC, PPARG, and STAT3 had the best value and became the gene doth the Lampeni leaf compound.These targets are tightly associated with inflammatory and proliferation processes, which explain the possible explaining Lampeni leaf in attenuating hyperlipidemic symptoms.Further study is needed to validate the result other than by molecular docking method, such as molecular dynamics, in vitro, or in vivo studies.